ghk-cu copper peptide 89030-95-5 Gly-His-Lys-Cu Tripeptide-1; Prezatide copper Discover the power of copper peptides in this advanced GHK-CU – Research Peptide |
Description
The majority of research conducted in adults with sermorelin and other modified versions of GRF (1-29) report dosages from 500g to 2000g (0.5-2mg) daily and report favorable safety profiles [15, 16, 17]
Downregulation of lncRNA UCA1 Facilitates Apoptosis and Reduces Proliferation in Multiple Myeloma via Regulation of the miR-1271-5p/HGF axis
doi:10.1210/endo.142.12.8522 Heffernan MA, Thorburn AW, Fam B, et al
I fully intend to get the second dose but this is weird
FDA submission is anticipated late 2026 / early 2027 per Eli Lilly investor communications
